This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.

AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.

Pfizer shares fell nearly 3 percent in the pre-market trading Monday following Moderna’s announcement.

The US government has selected three vaccine candidates to fund their Phase 3 trials through Operation Warp Speed.

Moderna has received approximately $400 million of customer deposits as of July 31, 2020 for potential supply of mRNA-1273.